Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R)

INTRODUCTION: Osteosarcoma overall survival has plateaued around 70%, without meaningful improvements in over 30 years. Outcomes for patients with overt metastatic disease at presentation or who relapse are dismal. In this study we investigated a novel osteosarcoma therapy utilizing radioimmunothera...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Nucl Med Biol
Huvudupphovsmän: Geller, David S., Morris, Jonathan, Revskaya, Ekaterina, Kahn, Mani, Zhang, Wendong, Piperdi, Sajida, Park, Amy, Koirala, Pratistha, Guzik, Hillary, Hall, Charles, Hoang, Bang, Yang, Rui, Roth, Michael, Gill, Jonathan, Gorlick, Richard, Dadachova, Ekaterina
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2016
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5118104/
https://ncbi.nlm.nih.gov/pubmed/27744117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nucmedbio.2016.07.008
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk